We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First-Ever SARS-CoV-2 Antibody Test Indicates Whether Patients Require COVID-19 Booster

By LabMedica International staff writers
Posted on 23 Jun 2022
Image: PictArray SARS-CoV-2 Antibody Test has received CE Mark (Photo courtesy of Pictor)
Image: PictArray SARS-CoV-2 Antibody Test has received CE Mark (Photo courtesy of Pictor)

The COVID-19 pandemic remains a healthcare concern as new strains of the virus have emerged. Now, a first-of-its-kind test enables personalized COVID-19 assessments by detecting if a patient has antibodies from a previous infection of SARS-CoV-2 or from vaccination alone.

The PictArray SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test from Pictor Limited (Auckland, New Zealand) detects if a person has antibodies from a previous SARS-CoV-2 infection (from spike protein (SP) and nucleocapsid protein (NP) antibodies) or from COVID-19 vaccination alone (SP antibodies only). The test also indicates whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative).

Pictor has received confirmation of CE registration for its PictArray SARS-CoV-2 IgG ELISA antibody test as per In Vitro Diagnostic Directive (IVDD) regulations, allowing it to market the COVID-19 antibody test in Europe and gain regulatory approval in Southeast Asia.

“Receiving CE registration enables Pictor to establish a footprint with partner laboratories and research bodies within Europe which is an important market for us,” said Howard Moore, CEO of Pictor. “Our recent successful funding round means we are well equipped to support market development and launches within the European Economic Area while continuing existing work across ANZ, the U.S., India and Southeast Asia.”

“As we learn more about COVID-19, the separate detection of SP and NP will enable a more precise assessment of a patient’s immunity against SARS-CoV-2 and help guide any associated clinical interventions whilst also informing wider public health measures when mass serosurveys are conducted,” added Pictor’s Chief Medical Officer Tadd Lazarus, MD.

Related Links:
Pictor Limited 

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Serological Pipet Controller
PIPETBOY GENIUS
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel

DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
PURITAN MEDICAL